The relationship between fractional exhaled nitric oxide and asthma symptom scores in patients on mepolizumab

D. Jackson (London, United Kingdom), L. Shackshaft (London, United Kingdom), L. Green (London, United Kingdom), C. Roxas (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), G. D'Ancona (London, United Kingdom), M. Elstad (London, United Kingdom), A. Douiri (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom)

Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Session: FeNO in airway diseases and asthma-COPD overlap identification
Session type: Thematic Poster
Number: 2623
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Jackson (London, United Kingdom), L. Shackshaft (London, United Kingdom), L. Green (London, United Kingdom), C. Roxas (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thompson (London, United Kingdom), G. D'Ancona (London, United Kingdom), M. Elstad (London, United Kingdom), A. Douiri (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), B. Kent (London, United Kingdom). The relationship between fractional exhaled nitric oxide and asthma symptom scores in patients on mepolizumab. 2623

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Usefulness of fractional exhaled nitric oxide (FeNO) for early diagnosis of asthma in patients with nonspecific respiratory symptoms
Source: Annual Congress 2009 - From cough to sound analysis of breathing
Year: 2009


The relationship between exhaled nitric oxide and compliance/adherence in patients with bronchial asthma using inhaled corticosteroids
Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases
Year: 2012

Comparisons for concentration in exhaled nitric oxide between patients with bronchial asthma and COPD
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007


Salt chamber treatment had no effect on fractional exhaled nitric oxide (FeNO) in patients with symptoms suggesting asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008

In current smokers fraction of exhaled nitric oxide is not associated with asthma symptoms
Source: Annual Congress 2010 - Asthma: breath biomarkers and asthma control
Year: 2010

Fractional exhaled nitric oxide (FeNO) for an early diagnosis of asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 677s
Year: 2006

Is exhaled nitric oxide (eNO) an indipendent outcome measure in chronic stable asthma?
Source: Eur Respir J 2002; 20: Suppl. 38, 196s
Year: 2002

The effect of phosphogliv admission on exhaled nitric oxide level in patients with bronchial asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 281s
Year: 2005

The effect of phosphogliv admission on exhaled nitric oxide level in patients with bronchial asthma
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010

Using fractional exhaled nitric oxide level to differentiate asthma–COPD overlap syndrome from COPD
Source: International Congress 2018 – Airway disease: recent discoveries
Year: 2018

The clinical utility of exhaled nitric oxide (eNO) in asthma, the first 1,000 patients
Source: Eur Respir J 2004; 24: Suppl. 48, 304s
Year: 2004

Exhaled nitric oxide (FeNO) in relation to exacerbation of childhood asthma
Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma
Year: 2009

Stability of exhaled nitric oxide (FENO) in patients with severe, steroid-dependent asthma
Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement
Year: 2008


Clinical usefulness of fractional exhaled nitric oxide (FeNO) as a marker of long-term asthma control
Source: Annual Congress 2009 - Airway inflammation and asthma control
Year: 2009

Clinical utility of fractional exhaled nitric oxide in severe asthma management
Source: Eur Respir J, 55 (3) 1901633; 10.1183/13993003.01633-2019
Year: 2020



Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009

Rint, exhaled nitric oxide and the prediction of asthma and respiratory symptoms in children
Source: Eur Respir J 2005; 26: Suppl. 49, 479s
Year: 2005

The effect of inhaled corticosteroid therapy on exhaled nitric oxide and exhaled hydrogen peroxide in asthma patients
Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers vs induced sputum
Year: 2006


Exercise training and exhaled nitric oxide (eNO) in COPD patients of different severity
Source: Eur Respir J 2001; 18: Suppl. 33, 222s
Year: 2001

Relationship between fractional exhaled nitric oxide and nasal symptom in allergic rhinitis
Source: Annual Congress 2010 - Asthma: breath biomarkers and asthma control
Year: 2010